Home  Management


Martin Bonde, Ph.D, B.Comm.
  • Serial entrepreneur, founded and managed several companies in Denmark and the US (NatImmune A/S, Arpida A/S, Combio A/S, CelTor Inc., Torsana Biosensor)
  • Fronted several successful exits over the last decade (NatImmune A/S to IPC, Combio A/S to Arpida AG, Torsana Biosensor A/S to Celtor Inc) as well as heading out-licensing, acquisitions, in-licensing etc.
Kristian Helin, Ph.D.
  • World leader in the field of oncology, epigenetics and histone modifying enzymes
  • Founded EpiTherapeutics with members of his laboratory at Biotech Research & Innovation Centre (BRIC), University of Copenhagen
  • Professor and Founding Director of BRIC, University of Copenhagen and Danish national Research Foundation’s Centre for Epigenetics
  • More than 100 papers in high impact journals including Nature, Cell and Genes & Development
  • Former divisional director of the European Institute of Oncology in Milan
Business Development Director
Henrik Blou, M.Sc.
  • CEO of Aros Pharma ApS
  • Founder, CEO/COO of MycoTeQ A/S
  • Management consultant with McKinsey & Company focusing on operations management, M&A and procurement in the pharma industry
  • Consultant to various biotech companies
Executive Vice President R&D
Lars-Ole Gerlach, Ph.D.
  • Director of Pharmacology and Head of in vitro pharmacology at 7TM Pharma
  • Ph.D. in molecular Pharmacology from University of Copenhagen & Post doc at University of Pennsylvania
  • Extensive experience with small molecule drug development
Executive Vice President and CMO
MUDr. Ivan Melezínek, CSc.
  • Deputy Head of Oncology at Merck KgaA and various other positions at Merck KgaA, Hoffmann LaRoche, AstraZeneca and Zeneca
  • M.D. and Ph.D. (CSc.) in biochemistry of malignant melanoma from Charles University School of Medicine in Prague
  • 23 years of experience in pharma oncology clinical development
2009 © Epitherapeutics A/S. All rights reserved.